Search Results for “biotechnology” – Page 25 – media

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018.
- Source: Prnewswire
- 747
- January 19, 2018
anti-cancer immune New Approvals RM-1929
Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.

Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.
- Source: globalenergymedia
- 543
- January 17, 2018
financing Natural products organic biomolecules Pfizer small molecule
FDA clears Shire’s dosing software for haemophilia A SHARE

Irish biotechnology firm Shire has received 510(k) marketing clearance for its myPKFiT for ADVATE [Antihemophilic Factor (Recombinant)] software from the US Food and Drug Administration (FDA).
- Source: medicaldevice-network
- 603
- December 26, 2017
ADVATE FDA haemophilia A Shire
Carmot Enters a Multi-Year Drug Discovery Collaboration With Amgen

Carmot Therapeutics, (Berkeley, CA) announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas.
- Source: Bestsellermagazine
- 532
- December 11, 2017
Amgen Market Views Parkinson’s disease
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.
- Source: Businesswire
- 557
- December 8, 2017
CAR–T Market Views Series
metaLinear Secures 255K Pound Seed Investment for Targeted Antibacterial Research

MetaLinear is a start-up biotechnology company founded in 2017, focused on the identification and validation of new drug targets for difficult to treat bacterial infections. The new investment was secured from the BioCity Group Ltd, who manage the Alderley Park Ventures (APV) fund and Catapult Ventures, who manage the Greater Manchester and Cheshire (GM&C) Life Sciences Fund. Both funds look to back innovative, high-technology companies providing much needed early stage finance.
- Source: biocity.co.uk;
- 476
- December 1, 2017
bacterial infections Market Views new drug
Medical Products for Human Use

New technologies, therapies and medicines are emerging; this includes regenerative medicine, more personalised treatments, as well as the development of nanomedicines. The Commission is committed to monitoring scientific progress and to constantly review Community legislation in the light of new developments so as to make safe, novel treatments available to patients as early as possible.
- Source: ec.europa.eu
- 634
- November 28, 2017
nanomedicine polices regenerative medicine
Brief Report on Exports of Chinese Vaccines in the First Three Quarters of 2017

In the first three quarters of 2017, the export sales of Chinese vaccines were 47.12 million USD with a slight increase of 6% over the same period of 2016.
- Source: Ddu
- 1,523
- November 27, 2017
export Market Reports vaccine
Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 644
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche
Sanofi Taps into Berg’s AI Platform for Developing Better Flu Vaccine

Machine learning technologies have already made huge strides in supporting the efforts of pharmaceutical companies in developing personalized medicines and novel biomarkers. This has been found to be helpful, notably for understanding the efficacy of prophylactic vaccines used for combating infectious diseases.
- Source: researchmoz.us
- 640
- November 8, 2017
Artificial Intelligence Market Views vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.